Pharsight

Edarbyclor is owned by Azurity.

Edarbyclor contains Azilsartan Kamedoxomil; Chlorthalidone.

Edarbyclor has a total of 5 drug patents out of which 0 drug patents have expired.

Edarbyclor was authorised for market use on 20 December, 2011.

Edarbyclor is available in tablet;oral dosage forms.

Edarbyclor can be used as treatment of hypertension.

The generics of Edarbyclor are possible to be released after 01 July, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584	AZURITY	Benzimidazole derivative and use thereof	May, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (1 year, 9 months from now)
US9066936	AZURITY	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent	Mar, 2028 (5 years from now)
US9169238	AZURITY	Solid pharmaceutical composition	Feb, 2030 (6 years from now)
US9387249	AZURITY	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone	Jul, 2031 (8 years from now)